1. Kunisaki C, Akiyama H, Nomura M, Matsuda G, Otsuka Y, Ono H, et al. Significance of long-term follow-up of early gastric cancer. Ann Surg Oncol. 2006; 13:363–369. PMID:
16485155.
Article
2. Kwon IG, Cho I, Guner A, Kim HI, Noh SH, Hyung WJ. Minimally invasive surgery as a treatment option for gastric cancer in the elderly: comparison with open surgery for patients 80 years and older. Surg Endosc. 2015; 29:2321–2330. PMID:
25480603.
3. Ge Z, Ben Q, Qian J, Wang Y, Li Y. Diabetes mellitus and risk of gastric cancer: a systematic review and meta-analysis of observational studies. Eur J Gastroenterol Hepatol. 2011; 23:1127–1135. PMID:
21934509.
4. Lee W, Ahn SH, Lee JH, Park DJ, Lee HJ, Kim HH, et al. Comparative study of diabetes mellitus resolution according to reconstruction type after gastrectomy in gastric cancer patients with diabetes mellitus. Obes Surg. 2012; 22:1238–1243. PMID:
22179701.
Article
5. Kim JH, Huh YJ, Park S, Park YS, Park DJ, Kwon JW, et al. Multicenter results of long-limb bypass reconstruction after gastrectomy in patients with gastric cancer and type II diabetes. Asian J Surg. 2020; 43:297–303. PMID:
31060769.
Article
6. Kim JW, Cheong JH, Hyung WJ, Choi SH, Noh SH. Outcome after gastrectomy in gastric cancer patients with type 2 diabetes. World J Gastroenterol. 2012; 18:49–54. PMID:
22228970.
Article
7. Guner A, Cho M, Son T, Kim HI, Noh SH, Hyung WJ. Improved glycemic control with proximal intestinal bypass and weight loss following gastrectomy in nonobese diabetic gastric cancer patients. Oncotarget. 2017; 8:104605–104614. PMID:
29262665.
Article
8. Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, et al. Bariatric surgery versus intensive medical therapy for diabetes: 5-year outcomes. N Engl J Med. 2017; 376:641–651. PMID:
28199805.
9. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Nanni G, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2015; 386:964–973. PMID:
26369473.
Article
10. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care. 2006; 29:1130–1139. PMID:
16644654.
11. Griffen SC, Wang J, German MS. A genetic defect in beta-cell gene expression segregates independently from the fa locus in the ZDF rat. Diabetes. 2001; 50:63–68. PMID:
11147796.
12. Topp BG, Atkinson LL, Finegood DT. Dynamics of insulin sensitivity, -cell function, and -cell mass during the development of diabetes in fa/fa rats. Am J Physiol Endocrinol Metab. 2007; 293:E1730–E1735. PMID:
17895283.
Article
13. Finegood DT, McArthur MD, Kojwang D, Thomas MJ, Topp BG, Leonard T, et al. Beta-cell mass dynamics in Zucker diabetic fatty rats: rosiglitazone prevents the rise in net cell death. Diabetes. 2001; 50:1021–1029. PMID:
11334404.
14. Weir GC, Laybutt DR, Kaneto H, Bonner-Weir S, Sharma A. Beta-cell adaptation and decompensat ion dur ing the progression of diabetes. Diabetes. 2001; 50 Suppl 1:S154–S159. PMID:
11272180.
15. Speck M, Cho YM, Asadi A, Rubino F, Kieffer TJ. Duodenal-jejunal bypass protects GK rats from {beta}-cell loss and aggravation of hyperglycemia and increases enteroendocrine cells coexpressing GIP and GLP-1. Am J Physiol Endocrinol Metab. 2011; 300:E923–E932. PMID:
21304061.
16. Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME. Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat. Diabetes. 2004; 53:989–997. PMID:
15047614.
Article
17. Rubino F, Forgione A, Cummings DE, Vix M, Gnuli D, Mingrone G, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006; 244:741–749. PMID:
17060767.
Article
18. Kang KC, Shin SH, Lee YJ, Heo YS. Influence of gastrectomy for stomach cancer on type 2 diabetes mellitus for patients with a body mass index less than 30 kg/m(2). J Korean Surg Soc. 2012; 82:347–355. PMID:
22708096.
Article
19. Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg. 2004; 239:1–11. PMID:
14685093.
20. Meirelles K, Ahmed T, Culnan DM, Lynch CJ, Lang CH, Cooney RN. Mechanisms of glucose homeostasis after Roux-en-Y gastric bypass surgery in the obese, insulin-resistant Zucker rat. Ann Surg. 2009; 249:277–285. PMID:
19212182.
Article
21. Pick A, Clark J, Kubstrup C, Levisetti M, Pugh W, Bonner-Weir S, et al. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes. 1998; 47:358–364. PMID:
9519740.
Article
22. Jones HB, Nugent D, Jenkins R. Variation in characteristics of islets of Langerhans in insulin-resistant, diabetic and non-diabetic-rat strains. Int J Exp Pathol. 2010; 91:288–301. PMID:
20384904.
Article
23. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology. 2002; 143:4397–4408. PMID:
12399437.
Article
24. Kaneto H, Miyatsuka T, Shiraiwa T, Yamamoto K, Kato K, Fujitani Y, et al. Crucial role of PDX-1 in pancreas development, beta-cell differentiation, and induction of surrogate beta-cells. Curr Med Chem. 2007; 14:1745–1752. PMID:
17627512.
25. Manning BD, Toker A. AKT/PKB signaling: navigating the network. Cell. 2017; 169:381–405. PMID:
28431241.
Article
26. Hers I, Vincent EE, Tavaré JM. Akt signalling in health and disease. Cell Signal. 2011; 23:1515–1527. PMID:
21620960.
Article
27. Beg M, Abdullah N, Thowfeik FS, Altorki NK, McGraw TE. Distinct Akt phosphorylation states are required for insulin regulated Glut4 and Glut1-mediated glucose uptake. Elife. 2017; 6:e26896. PMID:
28589878.
Article
28. Lanzarini E, Csendes A, Lembach H, Molina J, Gutiérrez L, Silva J. Evolution of type 2 diabetes mellitus in non morbid obese gastrectomized patients with Roux en-Y reconstruction: retrospective study. World J Surg. 2010; 34:2098–2102. PMID:
20532768.
Article
29. Lee TH, Lee CM, Park S, Jung DH, Jang YJ, Kim JH, et al. Long-term follow-up for type 2 diabetes mellitus after gastrectomy in non-morbidly obese patients with gastric cancer: the legitimacy of onco-metabolic surgery. J Gastric Cancer. 2017; 17:283–294. PMID:
29302369.
Article
30. Park YS, Park DJ, Kim KH, Park DJ, Lee Y, Park KB, et al. Nutritional safety of oncometabolic surgery for early gastric cancer patients: a prospective single-arm pilot study using a historical control group for comparison. Surg Endosc. 2020; 34:275–283. PMID:
30927123.
Article